Change from baseline in quality of life ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in disease severity according to participants ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Participant satisfaction · people with eczema
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
It is very uncertain whether topical active treatment in combination with moisturiser changes number of participants reporting an adverse event compared with topical active treatment alone (very low certainty).
1 finding from 1 review
Amount of corticosteroids used · people with eczema
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
Topical active treatment in combination with moisturiser may leads to lower number of participants who experienced a flare compared with topical active treatment alone (low certainty).
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in health‐related quality of life · people with eczema
1 finding from 1 review
Change from baseline in health‐related quality of life · people with eczema
1 finding from 1 review
Change from baseline in disease severity as assessed by the participants (number of participants who considered their skin to have improved) · people with eczema
Atopiclair probably leads to higher change from baseline in disease severity according to participants… compared with vehicle (moderate certainty).
1 finding from 1 review
Participant satisfaction · people with eczema
1 finding from 1 review
Proportion of participants with complete cure · children with tinea capitis
Complete cure and adverse events for terbinafine showed no clear difference in proportion of participants with complete cure compared with griseofulvin (low certainty).
4 findings from 1 review
RR 1.06 [0.98, 1.15]
3 studies · 328 participants
Low
RR 1.18 [0.74, 1.88]
1 study · 1006 participants
Low
RR 0.68 [0.53, 0.86]
2 studies · 334 participants
Moderate
Show 1 more finding
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for ketoconazole showed no clear difference in proportion of participants with complete cure compared with griseofulvin (low certainty).
2 findings from 1 review
Proportion of participants with complete cure · children with tinea capitis
Complete cure for fluconazole showed no clear difference in proportion of participants with complete cure compared with griseofulvin (moderate certainty).
2 findings from 1 review
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for fluconazole showed no clear difference in the proportion of participants with complete cure compared with terbinafine (low certainty).
1 finding from 1 review
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for fluconazole showed no clear difference in proportion of participants with complete cure compared with itraconazole (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of participants with complete cure · children infected with T. tonsurans and M. canis
The intervention showed no clear difference in proportion of participants with complete cure (low certainty).
1 finding from 1 review
Adverse events attributed to the study drugs · children with tinea capitis
Complete cure and adverse events for terbinafine showed no clear difference in adverse events attributed to the study drugs compared with griseofulvin (moderate certainty).
1 finding from 1 review
Severe adverse events · children with tinea capitis
Complete cure and adverse events for terbinafine showed no clear difference in severe adverse events compared with griseofulvin (moderate certainty).
1 finding from 1 review